Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00633750 · ClinicalTrials.gov registry record · Phase 2
Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery
A Phase 2 study, sponsored by Vanderbilt-Ingram Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
NCT00633750 is a Phase 2 study that has completed, run by Vanderbilt-Ingram Cancer Center. The registered enrollment target is 50 participants.
The verdict
NCT00633750, a Phase 2 study, has completed, sponsored by Vanderbilt-Ingram Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
Study Summary
RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well erlotinib works in treating patients with breast cancer that can be removed by surgery.
Interventions
- GENETIC protein expression analysis
- OTHER laboratory biomarker analysis
- OTHER immunohistochemistry staining method
- DRUG erlotinib hydrochloride
- GENETIC TUNEL assay
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2002-08 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00633750
The ClinicalTrials.gov registry entry for NCT00633750 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vanderbilt-Ingram Cancer Center, which has 189 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which protein expression analysis is the first listed.
NCT00633750 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00633750 about?
NCT00633750 is a clinical study titled "Erlotinib in Treating Patients With Breast Cancer That Can Be Removed by Surgery". RATIONALE: Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving erlotinib before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed. PURPOSE: This phase II trial is studying how well erlotinib wor...
What is the current status of trial NCT00633750?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2002-08. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00633750?
The interventions under investigation include: protein expression analysis (GENETIC), laboratory biomarker analysis (OTHER), immunohistochemistry staining method (OTHER), erlotinib hydrochloride (DRUG), TUNEL assay (GENETIC).
Who is sponsoring clinical trial NCT00633750?
This trial is sponsored by Vanderbilt-Ingram Cancer Center, which has 189 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.